Tehran University of Medical Sciences

Science Communicator Platform

Share By
Hemagglutinin-Esterase Cannot Be Considered As a Candidate for Designing Drug Against Covid-19 Publisher Pubmed



Zandi M1, 2 ; Soltani S1, 2
Authors

Source: Molecular Diversity Published:2021


Abstract

We read with interest the article by Patel et al. on the identification of potential inhibitors of coronavirus hemagglutinin-esterase. The authors considered hemagglutinin-esterase as a glycoprotein of SARS-CoV-2 and selected hemagglutinin-esterase as a target to identify potential inhibitors using a combination of various computational approaches, and however, SARS-CoV-2 genome lacks hemagglutinin-esterase gene; thus, hemagglutinin-esterase does not exist in SARS-CoV-2 particle. Graphic abstract: [Figure not available: see fulltext.]. © 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Other Related Docs
11. Potential Therapeutic Options for Covid-19: An Update on Current Evidence, European Journal of Medical Research (2022)
15. Molecular Aspects of Co-Morbidities in Covid-19 Infection, Archives of Bone and Joint Surgery (2020)
16. The Spike Protein Mutations and Its Effect on Sars-Cov-2 Pathogenesis, Journal of Cellular and Molecular Anesthesia (2021)
18. Variable Clinical Manifestations of Covid-19: Viral and Human Genomes Talk, Iranian Journal of Allergy# Asthma and Immunology (2020)